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A B S T R A C T
Nyaope is a mixture of low grade heroin, cannabis products, antiretroviral drugs and other materials
added as bulking agents. It is a highly physically additive mixture which is smoked by users. As part of
the development of a method for the analysis and proﬁling of nyaope this study evaluates the stability
of the cannabinoid, opiate and antiretroviral components of nyaope during storage following seizure.
Conditions used were those typically used for storage of drug seizures: in a desiccator in a refrigerator,
in a desiccator in the dark at room temperature, in a desiccator in daylight at room temperature and
ambient room temperature in the dark in a cabinet used for storage of drug seizures. Street samples of
cannabis (D9-tetrahydrocannabinol) and heroin were mixed with efavirenz and nevirapine tablets to
mimic a nyaope sample. The samples were homogenized and transferred into glass bottles and
extracted with tertiary butyl alcohol (tBuOH) and analysed by gas chromatography – mass
spectrometry (GC–MS) after the powdered drugs had been stored for intervals of 0 and 24 h under
each storage condition. The data obtained indicates that the target drug components in nyaope
samples decompose and that for comparison purposes the drug extracts should be prepared in tBuOH
immediately after seizure because of the decomposition of the drug components during storage prior
to extraction and analysis. The implications of this work are that law enforcement agencies dealing
with nyaope and wanting to compare drug samples may need to change their practice around how the
drug is handled after seizure but prior to analysis.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The abuse of the cocktail drug nyaope, in South Africa, has
increased in recent years mainly amongst young African and
Coloured males. This often results in these young males turning to
theft, losing their jobs and/or dropping out of school. The nyaope
users, who are mostly poor, often resort to criminal activities to
sustain their drug habit which includes stealing anything valuable
that they can lay their hands on [1–4].
Chemical comparisons of nyaope will assist relevant stake-
holders in prosecuting those involved in the manufacture,
trafﬁcking and distribution of the drug. It will also allow
determination of the drug and other content of the mixture so
that public health awareness programmes can be developed.* Corresponding author.
E-mail address: mthembim@saps.gov.za (P.M. Mthembi).
https://doi.org/10.1016/j.forsciint.2019.04.040
0379-0738/© 2019 The Authors. Published by Elsevier B.V. This is an open access article unNyaope contains heroin in combination with cannabis and other
adulterants which may include phenacetin (PNT), caffeine, efavirenz
(EFV), dextromethorphan (DTM) and nevirapine (NVP) [5,6]. Street
samples of heroin have been shown to contain diamorphine (DAM)
together with acetylcodeine (ACOD) and 6-monoacetylmorpine (6-
MAM) [5–7]. The combination of heroin, cannabis and antiretroviral
(ARV) drugs may be prepared by the drug dealers or mixed together
by the users of the drugs themselves resulting in a mixture of powder
and plant materials. The resulting drug cocktail is mixed with
tobacco and smoked (Fig. 1).
Whilst the cannabis may now, with changes in the legislation in
RSA, be grown at home it may also be bought illegally on the street.
The heroin is sourced illegally. The ARV’s can be derived from a
number of different sources. The use of ARVs as bulking agents for
nyaope has reportedly led to health professionals being robbed or
even corrupt ofﬁcials selling the ARVs [8–10]. HIV positive patients
are also either robbed or sell the ARVs themselves therebyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Illustrative sample of nyaope.
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psychiatric side-effects of efavirenz include, agitation, deperson-
alisation, hallucinations, disturbed dreams, mood disorders,
depression, suicidality, antisocial behaviour, psychosis, catatonia
and delirium [11,12]. Efavirenz has hallucination effect similar to
lysergic acid diethylamide (LSD) [13] and this serve as motivation
for its use with cannabis in the nyaope mixture.
Table 1 shows the structures of the signiﬁcant cannabinoid,
opiate and antiretroviral components of nyaope, and their
degradation products, which have been used for comparison of
samples in previous studies of the individual drugs. The presence
or otherwise of some of these drugs, for example cannabinol, allow
determination of whether the sample is degrading or not. The
degradation of any components may lead to erroneous chemical
comparisons being made [14]. Degradation of drug samples can
occur at any stage in the life cycle of a drug case including the
storage of the drug after seizure. Therefore storage conditions that
minimize the degradation of the components of nyaope, which
include opiates that hydrolyze, and cannabinoids which oxidise,
are necessary for successful comparison of nyaope samples.
There have been a number of studies of individual components of
nyaope under different storage conditions. Under long term storage,
cannabis, in the absence of direct light, has been shown to degrade to
a lesser extent when stored at 4 C than at 22 C [15]. The active
ingredient, D9-tetrahydrocannabinol (D9-THC) degrades to the less
potent cannabinol (CBN) [16,17], cannabidiol (CBD) degrades to
menthane carboxylic acid [18] while tetrahydrocannabivarin (THCV)
which is a propyl homolog of D9-THC [19,20] degrades to
cannabivarin (CBV) which is itself a homologue of CBN.
It is known that DAM hydrolyses to 6-MAM and then to
morphine (MOR) [21,22]. Under long-term storage (ﬁve weeks)
DAM was reported to undergo degradation (an average of 17.0%)
when stored in a refrigerator. When stored at ambient temperature
it degraded by an average of 23.3% [23].
ACOD is a synthetic impurity of illicit heroin usually present at
concentration levels of 15–20% relative to DAM and ranges up to
45% [24]. ACOD undergoes hydrolysis to codeine (COD) and
subsequently to MOR [25,26].
Efavirenz ((4S)-6-chloro-4-(cyclopropylethynyl)-4-(triﬂuro-
methyl)-1, 4-dihydro-2H-3, 1-benzoxazin-2-one) (EFV) was shown
to be stable in methanolic solution for at least 7 days and to undergo
degradation after 24 h of storage when exposed to UV light [27].EFV undergoes hydrolysis to an intermediate carbamic acid ({4-
Chloro-2-[(1S)-3-cyclopropyl-1-hydroxy-1-(triﬂouromethyl)prop-
2-yn-1 yl]phenyl}carbamic acid) which subsequently forms efavir-
enz amino alcohol ((2S)-2-(2-amino-5-chlorophenyl)-4-cyclo-
propyl-1,1,1-triﬂuorobut-3-yn-2-ol) and carbon dioxide [28]. The
alcohol may undergo cyclization to form the quinoline derivative (6-
chloro-2-cyclopropyl-4-(triﬂuoromethyl)quinoline) [29].
The potential degradation products of nevirapine (NVP) are
reported to be ethyl nevirapine and descyclopropyl nevirapine
[30]. EFV stock solutions in methanol and NVP stock solution in
dimethyl sulfoxide were reported to be stable after 24 h of storage
at ambient temperatures, and 24 and 36 months of storage,
respectively, at 20 C [31]. EFV and NVP were reported to be
stable after 3 months of storage at 4 C and 20 C while EFV and
NVP were only stable up to 50 and 70 days respectively when
stored at ambient temperatures [32].
NVP has been shown to be relatively stable when exposed to
humidity, UV light and heat up to 2 days of storage [33] as well as in
acetonitrile up to 48 h of storage [34].
Although there is a considerable amount of literature on the
long-term stability of the individual components of nyaope, to our
knowledge there is no study of the stability of these compounds
when mixed. This study determines the stability of the drugs found
in nyaope samples over a 24 h period. This will provide information
on how nyaope samples should be stored after seizure to facilitate
drug identiﬁcation and comparison. This in turn will inform law
enforcement agencies around how such samples should be
processed and how reliable data may be obtained for law
enforcement purposes.
2. Material and methods
2.1. Chemicals
Tertiary butyl alcohol (t-BuOH) (ACS, Reag. Ph Eur) was
purchased from Merck and tetracosane 99% was purchased from
Sigma-Aldrich. Solvents were used as received without further
puriﬁcation. Efavirenz 600 mg tablets- PhD item 41,047 and
nevirapine 200 mg tablets- PhD item 41,071 were both donated
by Aspen Pharmacare. Cannabis and heroin street samples seized
by the South African Police Service (SAPS) were used to formulate
the simulated nyaope sample used for the study.
Table 1
Structures of the signiﬁcant cannabinoid, opiate and antiretroviral components of nyaope, and their degradation products.
Component Degradation product/s
D9-Tetrahydrocannabinol
Cannabinol
Tetrahydrocannabivarin
Cannabivarin
Acetylcodeine
Codeine Morphine
Diamorphine
6-Monoacetylmorphine Morphine
Efavirenz
Carbamic acid derivative Efavirenz amino alcohol Quinoline derivative
Nevirapine Descyclopropyl nevirapine Ethyl nevirapine
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The internal standard was prepared at a ﬁnal concentration of
0.02 mg/ml in t-BuOH which was used to dissolve the samples for
gas chromatography–mass spectrometry (GC–MS) analysis.
Tertiary butyl alcohol has previously been shown to be thesolvent of choice for the identiﬁcation, comparison and proﬁling
of nyaope samples in which, once prepared, the drugs were stable
prior to analysis [7]. The internal standard solutions were
subsequently used to extract the drug samples after storage at
the various time intervals under the different conditions ahead of
instrumental analysis.
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Street cannabis and heroin samples seized by the SAPS were
used to prepare simulated nyaope samples. The simulated samples
were prepared by mixing the heroin street sample, cannabis street
sample, EFV tablet sample and NVP tablet sample, to mimic as
closely as possible a typical street sample of nyaope. The heroin
street samples were determined to contain caffeine, DAM,
dextromethorphan (DMP), acetylcodeine (ACOD), 6-monoacetyl-
morphone (6-MAM), noscapine, papaverine and phenacetin (PNT)
using GC–MS analysis during routine case work at the SAPS
Forensic Science Laboratory (SAPS-FSL). Of these the ACOD and
DAM were considered as heroin markers (since they are known to
hydrolyse when they decompose) and D9-THC the cannabis marker
(since this is known to oxidise on decomposition) in this study.
The simulated nyaope samples were homogenised by grinding
using a mortar and pestle. Each powdered nyaope sample was
divided into aliquots ranging from 10.0 to 10.6 mg. To obtain data at
t = 0, 10.2 mg of the homogenised samples was weighed into a
15 ml head space vial. 3 ml of the internal standard solution was
added and the vial sealed. The mixture was then sonicated for
15 min [35,36]. The residue was ﬁltered off and the eluate divided
into three 800 ml portions into amber GC–MS vials, representing
each of the triplicate analyses. The remainder of the aliquoted
homogenised samples (Table 2) ranging between 10.0 mg–10.6 mg
were weighed into clear glass bottles. The sample bottles were
placed in (i) an opaque paper bag and stored in a desiccator in a
refrigerator, (ii) in a desiccator at room temperature in the dark,
(iii) in a desiccator under direct laboratory light (daylight) and (iv)
in an uncontrolled environment in a locker (ambient). A freezer at
20 C was not used for storage since the samples may be carried
and stored for indeterminate periods prior to seizure and storage.
Additionally, mobile freezers are not currently available to SAPS.
The samples were subsequently extracted and analysed after
storage intervals of 0, 24, 72 h and 1 and 2 weeks in the same way as
the t = 0 samples.
2.4. Instrumentation
GC–MS is the analytical method of choice for drugs analysis in
SAPS laboratories. Whilst LC–MS or LC–MS/MS may be theoreti-
cally preferable it is not an instrument currently available to SAPS-
FSL. GC–MS analysis was carried out using an Agilent Technologies
system (Chemetrix, RSA) consisting of a gas chromatograph (GC),
Agilent 7890A, and mass selective (MS) detector (Agilent 5975 CVL
MSD) with an auto sampler 7683 B series (1 ml injection).
Chromatographic separation was performed on a computer
controlled auto sampler used with a fused-silica capillary columnTable 2
Mass (mg) of samples used for each time interval under the different storage conditio
Time, hours Samples stored in the fridge Samples stored in
0 10.2 10.2 
24 10.4 10.3 
72 10.2 10.5 
168 (1) 10.6 10.3 
336 (2) 10.2 10.5 
672 (4) 10.2 10.3 
840 (5) 10.1 10.4 
1344 (8) 10.2 10.3 
1512 (9) 10.1 10.1 
1680 (10) 10.5 10.2 
1848 (11) 10.2 10.1 
2016 (12) 10.5 10.3 
Average 10.28 10.29 
Standard deviation 0.16 0.13 
%RSD 1.65 1.27 HP-5MS (30 m  0.25 mm, ﬁlm thickness 0.25 mm; J&W Scientiﬁc,
Folsom, CA, USA). Splitless injection was used at 280 C. The GC
oven temperature programme consisted of an initial temperature
of 100 C for 0.4 min, raised to 290 C at a ﬂow rate of 60 C/min,
held at 290 C for 2.4 min then raised to reach 316 C at 60 C/min
and held for 3 min. The total run time was 9.40 min. High-purity
helium (99.9995%) was used as the carrier gas, at a ﬂow rate of
1 mL/min. The MS parameters were as follows: interface tempera-
ture (280 C), inlet temperature (250 C), ion-source temperature
(230 C), electron ionization (EI) at 70 eV and the mass spectrom-
eter (quadrupole) used in scan mode. The spectra were recorded in
the scan range of 35–550 amu, at a scan rate of 1 scan/sec.
Tetracosane (C24) was used as the internal standard for GC–MS
analysis. The area of the total ion chromatograph of each peak of
interest was used to evaluate the stability of the samples under the
respective storage condition. The samples were analysed in
triplicate and the mean response, relative to tetracosane, per unit
mass of drug was calculated.
Prior to analysis, conﬁrmation that the instrument met QA
standards was achieved using a system suitability test according to
the SAPS-FSL protocol
3. Results and discussion
A typical separation of the components of nyaope is shown in
Fig. 2 with the retention times and retention indices relative to
tetracosane given in Table 3. The components DAM and D9-THC
were identiﬁed on the basis of their retention time and mass
spectral data using certiﬁed reference material. EFV, PNT, caffeine
and NVP were identiﬁed on the basis of their retention time and
mass spectral data using USP reference standards while the mass
spectral spectra libraries DD12 (designer drug 2012), SWGDRUG
and the NIST were used to identify THCV, CBV, cannabichromene
(CBC), CBD, cannabigerol (CBG), ACOD, CBN, 6-MAM, nonacosane;
papaverine and noscapine. The response areas of the analytes of
interest under the different storage conditions and period were
determined from total ion chromatograms.
It is known that the active ingredient of cannabis, D9 THC,
degradestoCBNbyoxidation[16].Therefore,ameasure ofstabilityof
the sample is the D9-THC concentration as assessed by the relative
response to the internal standard, per unit mass over time. It is also
known that ACOD and DAM both hydrolyse and that the ARV’s NVP
and EFV also decompose. The relative responses of these compounds
to the internal standard, per unit mass at t = 0 and t = 24 h are given in
Table 4. All compounds listed decompose in this time frame. The
greatest decomposition is seen in the ARV’s with as much as 42%
decomposition for NVP and 24% for EFV. With the exception of NVP,
the greatest decomposition as seem under ambient conditions, asns.
 the dark Samples stored in light Samples stored in ambient
uncontrolled environment
10.2 10.2
10.3 10.2
10.4 10.3
10.1 10.2
10.3 10.2
10.3 10.6
10.1 10.1
10.3 10.2
10.5 10.5
10.5 10.4
10.4 10.4
10.3 10.2
10.31 10.29
0.13 0.14
1.27 1.46
Fig. 2. Typical total ion chromatograph for the synthesised nyaope samples where (1) phenacetin; (2) caffeine; (3) efavirenz; (4) dextromethorphan;
(5) tetrahydrocannabivarin; (6) tetracosane (IS); (7) cannabivarin; (8) cannabichromene; (9) cannabidiol; (10) nevirapine; (11)D9-tetrahydrocannabinol; (12) cannabigerol;
(13) acetylcodeine; (14) cannabinol; (15) 6-monoacetylmorphine; (16) diamorphine; (17) nonacosane; (18) papaverine and (19) noscapine.
Table 3
Retention times and relative retention indices of individual components for the simulated nyaope sample.
Component Retention time (minutes) Relative retention index (tetracosane = 1.000)
Phenacetin 3.266 0.572
Caffeine 3.691 0.646
Efavirenz 4.756 0.833
Dextromethorphan 4.885 0.855
Tetrahydrocannabivarin 5.520 0.967
Tetracosane 5.711 1.000
Cannabivarin 5.837 1.022
cannabichromene 5.993 1.049
Cannabidiol 6.016 1.053
Nevirapine 6.169 1.080
D9-tetrahydrocannabinol 6.458 1.131
Cannabigerol 6.668 1.168
Acetylcodeine 6.723 1.177
Cannabinol 6.754 1.183
6-monoacetylmorphine 6.820 1.194
Diamorphine 7.238 1.267
Nonacosane 7.765 1.360
Papaverine 7.969 1.395
Noscapine 9.888 1.731
Table 4
Relative responses of ACOD, DMA, THC, NVP and EFV to tetracosane, per unit mass of
nyaope, and percentage decomposition in 24 h.
Drug Time (hours) Fridge Dark Light Ambient
ACOD 0 0.065 0.065 0.065 0.065
24 0.063 0.062 0.062 0.056
Percentage decomposition 3% 5% 5% 14%
DAM 0 0.997 0.997 0.997 0.997
24 0.865 0.803 0.801 0.774
Percentage decomposition 13% 20% 20% 22%
THC 0 0.352 0.352 0.352 0.352
24 0.330 0.322 0.321 0.299
Percentage decomposition 6.3% 8.6% 8.9% 15%
NVP 0 0.262 0.262 0.262 0.262
24 0.151 0.190 0.156 0.176
Percentage decomposition 42% 27% 40% 32%
EFV 0 0.185 0.185 0.185 0.185
24 0.146 0.163 0.163 0.140
Percentage decomposition 21% 12% 12% 24%
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most when stored in the fridge. Using the non-parametric statistic
Wicoxon’s Signed Ranks Test for two groups, arranged as paired
observations [37], these differences are signiﬁcant at the 5% level. Onthis basis it can be concluded that signiﬁcant decomposition of the
samples is occurring in as little as 24 h.
On this basis, if samples are to be analysed for comparative
purposes, they should be extracted as soon as possible after
seizure, in tBuOH [7]. The solution can then be safely stored prior to
analysis for up to 72 h [7].
4. Conclusions
The drug markers for the proﬁling of cannabis include D9-THC
and THCV and for opiates include DAM and ACOD. This study
demonstrates that when mixed together in nyaope, with the
addition of the antiretrovirals, that decomposition of the drugs
starts within 24 h. The implications of this are that in order to
compare drug samples, extracts in tBuOH must be prepared
immediately after the drug is seized, and these need to be analysed
within 72 h [7]. If only drug identiﬁcation is required, the drugs are
qualitatively present in the samples for considerably longer time.
A further implication for drug comparison is that if two drug
samples have matching drug contents then it is likely that they
camefromaoncelargerbatchbecause it isextremelyunlikelythattwo
unrelated samples would decompose to give the same chromatogram
if they were seized, extracted and analysed under identical conditions.
192 P.M. Mthembi et al. / Forensic Science International 300 (2019) 187–192Conversely, if twosampleshavedifferent proﬁles it does not mean that
they were from a once larger sample or that they were not. Using the
organic drug compounds it is not possible to draw a conclusion
because the time of seizure and conditions of storage prior to analysis
would impact on the proﬁle. In terms of policing and forensic science
this study means that, for nyaope, decisions around whether an
identiﬁcation is required, ora comparison is to be made, must be made
at averyearlystage in the case. Forensic practitioners must be aware of
the requirements of the law enforcement agencies ahead of time. This
may require changes in the way that nyaope cases are handled and
processed by law enforcement agencies.
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